Development of Resistance to Type II JAK2 Inhibitors in MPN Depends on AXL Kinase and Is Targetable.
Codilupi T, Szybinski J, Arunasalam S, Jungius S, Dunbar AC, Stivala S, Brkic S, Albrecht C, Vokalova L, Yang JL, Buczak K, Ghosh N, Passweg JR, Rovo A, Angelillo-Scherrer A, Pankov D, Dirnhofer S, Levine RL, Koche R, Meyer SC.
Codilupi T, et al. Among authors: szybinski j.
Clin Cancer Res. 2024 Feb 1;30(3):586-599. doi: 10.1158/1078-0432.CCR-23-0163.
Clin Cancer Res. 2024.
PMID: 37992313
Free PMC article.